Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;108(10):2865-2871.
doi: 10.3324/haematol.2022.281552.

KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study

Blaine W Robinson  1 , John A Kairalla  2 , Meenakshi Devidas  3 , Andrew J Carroll  4 , Richard C Harvey  5 , Nyla A Heerema  6 , Cheryl L Willman  7 , Amanda R Ball  1 , Elliot C Woods  1 , Nancy C Ballantyne  1 , Karen A Urtishak  1 , Frederick G Behm  8 , Gregory H Reaman  9 , Joanne M Hilden  10 , Bruce M Camitta  11 , Naomi J Winick  12 , Jeanette Pullen  13 , William L Carroll  14 , Stephen P Hunger  15 , ZoAnn E Dreyer  16 , Carolyn A Felix  17
Affiliations

KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study

Blaine W Robinson et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier plots of event-free survival in COG P9407 trial. Event-free survival (EFS) in treatment-eligible infants estimated by Kaplan-Meier method as a function of: (A) KMT2A-G and KMT2A partner genes (11 treatment-eligible in category ‘unknown’ partner gene excluded); (B) age </>90 days in KMT2A-R overall (left), AAF1 (middle), and MLLT1 (right); (C) white blood cell (WBC) count </>50×109/L in KMT2A-R overall (left), MLLT1 (middle), and KMT2A-G (right); (D) male vs. female sex in KMT2A-R overall (left), and AAF1 (right); (E) central nervous system (CNS) status in KMT2A-R overall, and AAF1 (right). CNS1 (CNS-negative), CNS2 (positive cytomorphology but <5 WBC/µL), CNS3 (>5 WBC/µL and positive cytomorphology). (A-E) EFS calculated as time from diagnosis to first event (induction failure, relapse, secondary malignancy, remission death). Patients having no event were censored at last contact. Numbers of patients are indicated in the plots. P values calculated by log-rank test are at top right in the plots.
Figure 2.
Figure 2.
Correlations of demographic and clinical covariates with KMT2A-G and KMT2A partner genes. Distributions among KMT2A-G and AFF1, MLLT1, MLLT3, and ‘other’ KMT2A-R genetic subtypes for all treatment-eligible and treatment-ineligible infants plotted by: (A) age at diagnosis ≤90 days (d) vs. >90 d (top left), and age as a continuous variable (top right). Box and whisker plots (bottom) indicate that distribution by age in days as a continuous variable differs among genetic subtypes (χ statistic 30.2; degrees of freedom (DF) 4; P<0.0001). Error bars represent range; horizontal lines, quartiles; and small diamond, the mean. (B) Presenting white blood cell (WBC) count <50x109/L vs. ≥50x109/L (top left), and as a continuous variable (top right). Box and whisker plots (bottom) indicate that WBC distribution as a continuous variable differs among genetic subtypes (χ statistic 39.4; DF 4; P<0.0001). (A, B) Distributions among genetic subtypes were compared by Kruskal-Wallis χ square-test; (C) sex; (D) central nervous system (CNS) status at diagnosis. (A-D) Cases in ‘unknown’ partner gene category were excluded.
See this image and copyright information in PMC

References

    1. Hilden JM, Dinndorf PA, Meerbaum SO, et al. . Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441-451. - PMC - PubMed
    1. Pieters R, Schrappe M, De Lorenzo P, et al. . A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250. - PubMed
    1. Dreyer ZE, Hilden JM, Jones TL, et al. . Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer. 2015;62(3):419-426. - PMC - PubMed
    1. Pieters R, De Lorenzo P, Ancliffe P, et al. . Outcome of infants younger than 1 Year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study. J Clin Oncol. 2019;37(25):2246-2256. - PubMed
    1. Brown PA, Kairalla JA, Hilden JM, et al. . FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021;35(5):1279-1290. - PMC - PubMed

Publication types

Substances